Keywords: cti, stock, plummets, lisofylline, disappointment, ards, study

CTI stock plummets on lisofylline disappointment in ARDS study

Article | 02 June 1999

Print This

Cell Therapeutics Inc of Seattle, USA, saw its share price drop by morethan 50% after announcing that it has stopped a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in